Olanzapine
- Generic Name
- Olanzapine
- Brand Names
- Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N4S
- CAS Number
- 132539-06-1
- Unique Ingredient Identifier
- N7U69T4SZR
- Background
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...
- Indication
Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...
- Associated Conditions
- Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Antipsychotics and Risk of Hyperglycemic Emergencies
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2015-10-21
- Target Recruit Count
- 725489
- Registration Number
- NCT02582736
- Locations
- 🇨🇦
Women's College Hospital, Women's College Research Institute, Toronto, Ontario, Canada
Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder
- Conditions
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 54
- Registration Number
- NCT02562287
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Dost Ongur
- Target Recruit Count
- 35
- Registration Number
- NCT02536846
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2017-03-30
- Target Recruit Count
- 120
- Registration Number
- NCT02484911
- Locations
- 🇨🇳
First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 9
- Registration Number
- NCT02462473
Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Michael Rickels
- Target Recruit Count
- 15
- Registration Number
- NCT02447835
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Kunming Medical University
- Target Recruit Count
- 128
- Registration Number
- NCT02435654
- Locations
- 🇨🇳
Psychiatry Department,First Affiliated Hospial Of Kunming Medical University, Kunming, Yunnan, China
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 337
- Registration Number
- NCT02431702
A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- Korean South West Oncology Group
- Target Recruit Count
- 58
- Registration Number
- NCT02400866
IM Olanzapine Versus Haloperidol or Midazolam
- Conditions
- Interventions
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 167
- Registration Number
- NCT02380118
- Locations
- 🇭🇰
Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong
🇭🇰Prince of Wales Hospital, Hong Kong, Hong Kong
🇭🇰Ruttonjee Hospital, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.